Overview
- The Duquesne Family Office’s 13F filed August 14, 2026, lists Natera as its top holding at 16.6% of the reported portfolio after adding 122,700 shares to reach about 3.19 million shares worth roughly $864.9 million.
- Natera reported second‑quarter revenue of $752.8 million on August 6, 2026, a 37.7% year‑over‑year increase that beat Street estimates and came with roughly 1,043,900 tests processed in the quarter.
- Signatera, Natera’s tumor‑DNA blood test that detects cancer recurrence earlier than scans, is cited as the product driving oncology volume growth and recurring per‑test revenue from hospitals and insurers.
- Druckenmiller added to the position while the stock traded near record levels, a high‑conviction and concentrated bet that raises questions about position risk because 13F filings only show quarter‑end U.S. equity holdings.
- Analysts say the stake signals a shift for a veteran macro investor toward a product‑led healthcare bet and that near‑term catalysts to watch are continued Signatera adoption, reimbursement trends, and Natera’s path to positive cash flow.